ENGINEERING:

 

PUBLICATIONS:

 

1. Daniels-Wells TR, Pierre V. Candelaria PV, Kranz E, Wen J, Wang L, Kamata M, Almagro JC, Martínez-Maza O, Penichet ML. Efficacy of antibodies targeting transferrin receptor 1 in xenograft mouse models of AIDS-related non-Hodgkin lymphoma. 15: 1816. 2023.

 

2. Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML. Progress and challenges in the design and clinical development of antibodies for cancer therapy. Frontiers in Immunology. 8: 1751-1770, 2018.

 

ISSUED, FILED and PUBLISHED PATENTS:

 

 

1. Puro R, Hiebsch RR, Capoccia BJ., Andrejeva G, Almagro JC, Pereira DS. Therapeutic SIRP-alpha. antibodies.  Assignee: Arch Oncology, Inc. US Patent: 11,202,828. Issued: 12/21/2021.

 

1. Manning PT, Puro R, Almagro JC, Karr RW. Therapeutic CD47 antibodies. Assignee: Arch Oncology, Inc. Priority Date: 02/08/2019. US Patent: 10,844,124. Issued: 11/24/2020.

 

1. Manning P, Puro R, Almagro JC, Karr RW. Therapeutic CD47 Antibodies. US Patent: 10,239,945. Assignee: Arch Oncology, Inc. Issued: 03/26/2019.

 

1. Swanson RV, Chi E, Raghunathan G, Zhao S, Fransson J, Cordier W, Almagro JC, Hyun L, Giles-Komar J, O’Neil KT, Carton JM, Zhou HM, Teplyakov AV, Feng Y. Engineered Anti-IL-13 Antibodies, Compositions, Methods and Uses. US Patent: 8,323,646. Assignee: Centocor Ortho Biotech Inc.  Issued: 12/04/2012.

 

1. Almagro JC, Valadon P. Antibody libraries of improved functionality. Provisional Patent. Assignee: Antibody Design Labs and GlobalBio, Inc.  PCT: WO/2019/099454. Priority Date: 11/14/2017.

 

1. Penichet ML, Wells TR, Almagro JC. Composition and Methods for Transferrin Receptor 1 targeting. PCT: WO2021092482A1. Applicant: UCLA & Klyss Biotech, Inc. Priority Date: 11/06/2019.

 

1. Manning PT, Puro R, Almagro JC, Karr RW, Capoccia B.J. Combination therapy for the treatment of solid and hematological cancers. Assignee: Arch Oncology Inc. Application No.:  20190309066A1. Priority Date: 11/06/2017.

 

8. Nastri HG, Shaun MS, Almagro JC, Zhou J, Buonpane RA, Wang H, Chen Y, Wang X, Carlsen PN, Li Y, Qi C, Wu L, Yao W, Zhu W, Huang T. Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy. Assignee: Incyte Corporation. Application No.: US 2021/0230294 A1. Priority Date: 12/30/2020.

 

9. Nastri HG, Stewart SM, Almagro JC, Zhou J, Buonpane RA. Interferon beta antibodies and uses thereof. US Patent: 2021/0230293 A1. Assignee: Incyte Corporation. Priority Date: 12/30/2020.

 

10. Wang H, Almagro JC, Buonpane RA, Carlsen PN, Huang T, Li Y, Lin L, Nastri HG, Qi C, Stewart SM, Thekkat PU, Wang X, Wu L, Yao W, Zhou J, Zhu W. Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors. Application No.: 2021/0205311 A1. Assignee: Incyte Corporation. Priority Date: 12/30/2020.

 

11. Henry R, Samarakoon T, Fishkin N, Zhu P, Pazolli E, Palacino J, Almagro JC. Anti-BCMA antibody-drug conjugates and methods of use. Application No.: 2022/0081486 A1. Assignee: Eisai R&D Management Co Ltd. Priority Date: 04/06/2021.

 

12. Blinn J, Mckearn J, Monahan J, Strohl WR, Puro R, Richards J, Almagro JC. THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCER IN COMBINATION WITH ANALOGS OF INTERLEUKIN PROTEINS. US Patent App. 17/527,982, 2022.

 

13. H Wang, JC Almagro, RA Buonpane, PN Carlsen, T Huang, Y Li. Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies. US Patent App. 17/564,549, 2022.

 

14. Robyn P, Hiebsch RR, Capoccia BJ, Andrejeva G, Almagro JC. Therapeutic sirp-alpha antibodies US Patent App. 17/534,774, 2022.

 

ALTHEA Gold™ Libraries:

 

PUBLICATIONS:

 

 

1. Guzmán-Bringas OU, Gómez-Castellano K, González-González E, Salinas-Trujano J, Vázquez-Leyva S, Vallejo-Castillo L, Pérez-Tapia SM, Almagro JC. Discovery and optimization of neutralizing SARS-CoV-2 antibodies using ALTHEA Gold Plus Libraries™. J. Mol. Sci. 24: 4609. 2023.

 

2. González-González E, Carballo-Uicab G, Juana Salinas-Trujano J, María I. Cortés-Paniagua MI, Said Vázquez-Leyva S, Vallejo-Castillo L, Mendoza-Salazar I, Gómez-Castellano K, Pérez-Tapia SM, Almagro JC. In vitro and in vivo characterization of a broadly neutralizing anti-SARS-CoV-2 antibody isolated from a semi-immune phage display library. Antibodies. Antibodies (Basel). 11: 57. 2022

 

3. Almagro JC, Mellado-Sánchez G, Pedraza-Escalona M, Pérez-Tapia SM. Evolution of approved anti-SARS-COV-2 therapeutic antibodies. J. Mol. Sci. 23: 9763. 2022.

 

4. Mendoza-Salazar I, Gómez-Castellano KM, González-González E, Gamboa-Suasnavart R, Rodríguez-Luna SD, Santiago-Casas G, Cortés-Paniagua MIC, Pérez-Tapia SM, Almagro JC. Anti-SARS-CoV-2 Omicron antibodies isolated from a SARS-CoV-2 Delta semi-immune phage display library. Antibodies (Basel). 11: 2022.

 

5. Pedraza-Escalona M, Guzmán-Bringas O, Arrieta-Oliva I, Gómez-Castellano K, Salinas-Trujano J, Torres-Flores J, Muñoz-Herrera JC, Camacho-Sandoval R, Contreras-Pineda P, Chacón-Salinas R, Pérez-Tapia SM, Almagro JC. Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Libraries™. BMC Infectious Diseases. 21: 1121, 2021.

 

6. Camacho-Sandoval R, Nieto-Patlán A, Carballo-Uicab G; Montes A, Jiménez-Martínez MC, Vallejo-Castillo L, González-González E; Arrieta-Oliva HI, Gómez-Castellano K, Guzman-Bringas U, Cruz-Domínguez MP, Medina G, Montiel-Cervantes LA, Pérez-Tapia SM, Almagro JC. Development and Evaluation of a Set of Spike and Receptor Binding Domain-Based Enzyme-Linked Immunosorbent Assays for SARS-CoV-2 Serological Testing. 11: 1506, 2021.

 

7. Almagro JC, Pedraza M, Arrieta HI, Pérez-Tapia SM. Phage Display Libraries for Antibody Therapeutic Discovery and Development. Antibodies. 8: 44,

 

Valadon P, Pérez-Tapia SM, Nelson RS, Guzmán-Bringas OU, Arrieta-Oliva HI, Gómez-Castellano KM, Pohl MA, Almagro JC. ALTHEA Gold Libraries™: Antibody Libraries for Therapeutic Antibody Discovery. MAbs. 11: 516-531, 2019.